This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Diabetes, Metabolic Syndrome And Cardiovascular Disease

7.4.2 Current Status 152

7.5 Gastric Bypass Surgery to Treat Type 2 Diabetes 152

7.6 Immune Modulators 153

7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 153

7.8 Other Anti-Diabetic Therapy Drug Candidates 154

7.8.1 Lipid Abnormalities 154

7.8.2 High Blood Pressure 155

7.8.3 Anti-Coagulants and Anti-Platelets 156

7.9 Drugs Used "Off-Label" 157

7.9.1 Warfarin Sodium 157

8. Diagnosing Diabetes Using In Vitro Laboratory Tests 1588.1 New Diagnostic Guidelines 1588.2 Diabetes Tests 1598.2.1 Fasting Plasma Glucose (FPG) Test 1608.2.2 Glucose Tolerance Test 1608.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c) 1608.2.4 Fructosamine 1618.2.5 Screening Tests for Diabetes-Related Complications 1628.3 Glucose Monitoring 1628.3.1 Overview of Market Segment 1648.3.2 Competitive Strategies 1648.3.3 Analyses of the Current Market Conditions, Competition and Product Mix 1668.3.3.1 First-Generation Monitors 1678.3.3.2 Second-Generation Monitors 1678.3.3.3 Third-Generation SMBG Technologies 1688.3.3.4 Product Overview 1688.3.3.4.1 LifeScan 1688.3.3.4.2 Roche Diagnostics 1708.3.3.4.3 Bayer HealthCare 1728.3.3.4.4 Abbott Diabetes Care 1738.3.3.4.5 Other Players 1748.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device? 1758.3.5 Minimally-Invasive Continuous Glucose Monitors in Development 1768.3.6 Future of Non-Invasive Glucose Technology 1768.3.7 Lancets and Lancing Devices 176

9. Market Trends, Challenges and Strategic Options 180

9.1 Overview 180

9.2 Diabetes Drug Market Trends 180

9.2.1 Overview 180

9.2.2 Emergence of Therapeutics with Improved Administration Characteristics 180

9.2.3 Increasing Prevalence of Obesity 181

9.2.4 Consumer Preference Drives Product Development in Invasive Technology

Segment 182

9.2.5 Revenue Potential of Non-Invasive Technologies 182

9.3 Diabetes Mellitus Market Challenges 182

9.3.1 Overview 182

9.3.2 Diabetic Pain Therapeutics 183

9.3.3 Market Prospects of Inhalable Insulin 183

9.4 Strategic Options 183

9.4.1 Developing Countries are Key Markets for Growth 184

9.4.2 Consumer-Driven Marketing Campaigns 185

9.4.3 Diabetes Drugs in Pipeline 185

9.5 New FDA Guidelines for Developing Anti-Diabetic Drugs 186

9.6 Recent Industry Activity 187

10. Company Profiles 18910.1 A. Menarini 18910.2 Abbott Laboratories 18910.3 Amgen 19010.4 AstraZeneca 19010.5 Bayer Pharma 19210.6 BodyMedia 19410.7 Cyber Medical Ltd. 19410.8 Debiotech 19410.9 DexCom 19510.10 Echo Therapeutics 19610.11 Eli Lilly 19810.12 Elixir Pharmaceuticals 19810.13 Eksigent Technologies 19810.14 Flamel Technologies 19910.15 GlaxoSmithKline 19910.16 Insulet 19910.17 iSense Corporation 20010.18 Isis Pharmaceuticals, Inc. 20010.19 Johnson & Johnson 20110.20 Kyorin 20210.21 M-Biotech 20310.22 Medtronic 20310.23 Merck & Company 20310.24 Mitsubishi Tanabe Pharma Corporation 20410.25 Nipro Diagnostics 20410.26 Novartis 20410.27 Novo Nordisk 20510.28 Novocell 20610.29 ONO Pharmaceutical 20610.30 Orexigen Therapeutics 20710.31 Pfizer 20710.32 Roche Diagnostics 20810.33 Sanofi-Aventis 20910.34 Sensors for Medicine and Science 21010.35 Siemens 21110.36 Smiths Medical 21110.37 SOOIL Development 21210.38 Takeda 21210.39 TheraFuse 21210.40 U.S. Diagnostics 21310.41 VeraLight 21310.42 Vivus 21310.43 Ypsomed Holding 214

4 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs